Literature DB >> 11099266

Atypical antipsychotics.

S Kapur, G Remington.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 11099266      PMCID： PMC1119100          DOI： 10.1136/bmj.321.7273.1360

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.

Authors:  D C Henderson; E Cagliero; C Gray; R A Nasrallah; D L Hayden; D A Schoenfeld; D C Goff
Journal:  Am J Psychiatry       Date:  2000-06       Impact factor: 18.112

Review 2.  Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.

Authors:  J Geddes; N Freemantle; P Harrison; P Bebbington
Journal:  BMJ       Date:  2000-12-02

Review 3.  Antipsychotic-induced weight gain: a comprehensive research synthesis.

Authors:  D B Allison; J L Mentore; M Heo; L P Chandler; J C Cappelleri; M C Infante; P J Weiden
Journal:  Am J Psychiatry       Date:  1999-11       Impact factor: 18.112

4.  The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics.

Authors:  H Y Meltzer
Journal:  J Clin Psychopharmacol       Date:  1995-02       Impact factor: 3.153

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 6.  Motor and mental aspects of extrapyramidal syndromes.

Authors:  D E Casey
Journal:  Int Clin Psychopharmacol       Date:  1995-09       Impact factor: 1.659

7.  Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.

Authors:  S Leucht; G Pitschel-Walz; D Abraham; W Kissling
Journal:  Schizophr Res       Date:  1999-01-04       Impact factor: 4.939
  7 in total
  9 in total

1.  Atypical antipsychotics in the treatment of schizophrenia. Users' experiences of treatments must be considered.

Authors:  C Prior ; J Clements; M Rowett
Journal:  BMJ       Date:  2001-04-14

Review 2.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

3.  Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy.

Authors:  Margherita Andretta; Arcangelo Ciuna; Letizia Corbari; Andrea Cipriani; Corrado Barbui
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-01       Impact factor: 4.328

4.  Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol : Results of the EIRE Study.

Authors:  Julio Bobes; J Rejas; M Garcia-Garcia; F Rico-Villademoros; M P García-Portilla; M Madrigal; G Hernández
Journal:  Clin Drug Investig       Date:  2002-09       Impact factor: 2.859

Review 5.  Head-to-head comparison of the costs of atypical antipsychotics: a systematic review.

Authors:  Corrado Barbui; Camilla Lintas; Mauro Percudani
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 6.  Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective.

Authors:  Mauro Percudani; Corrado Barbui; Michele Tansella
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

7.  Predictors of switching antipsychotic medications in the treatment of schizophrenia.

Authors:  Allen W Nyhuis; Douglas E Faries; Haya Ascher-Svanum; Virginia L Stauffer; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2010-09-28       Impact factor: 3.630

8.  Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients : estimates from a prospective naturalistic study.

Authors:  David Salkever; Eric Slade; Mustafa Karakus
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 9.  Second-Generation Antipsychotics' Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders.

Authors:  Michele Fabrazzo; Salvatore Cipolla; Alessio Camerlengo; Francesco Perris; Francesco Catapano
Journal:  J Clin Med       Date:  2022-08-03       Impact factor: 4.964
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.